NEW YORK (GenomeWeb News) – Intrexon today announced an agreement to acquire adult stem cell technology firm Medistem for about $26 million.

Based in San Diego, Medistem develops endometrial regenerative cells, which are universal donor adult stem cells that stimulate new blood vessel formation. ERCs can generate different tissues such as heart, brain, pancreas, liver, bone, cartilage, and lung, and Intrexon plans to use its synthetic biology platforms to "engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs," it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.